RS60022B1 - 1,3-benzodioksol derivati kao ezh1 i/ili ezh2 inhibitori - Google Patents
1,3-benzodioksol derivati kao ezh1 i/ili ezh2 inhibitoriInfo
- Publication number
- RS60022B1 RS60022B1 RS20200240A RSP20200240A RS60022B1 RS 60022 B1 RS60022 B1 RS 60022B1 RS 20200240 A RS20200240 A RS 20200240A RS P20200240 A RSP20200240 A RS P20200240A RS 60022 B1 RS60022 B1 RS 60022B1
- Authority
- RS
- Serbia
- Prior art keywords
- ezh1
- ezh2 inhibitors
- benzodioxole derivatives
- benzodioxole
- derivatives
- Prior art date
Links
- 150000005529 1,3-benzodioxoles Chemical class 0.000 title 1
- 101150090105 Ezh2 gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014053235 | 2014-03-17 | ||
| PCT/JP2015/057652 WO2015141616A1 (ja) | 2014-03-17 | 2015-03-16 | １，３－ベンゾジオキソール誘導体 |
| EP15765525.9A EP3121175B1 (en) | 2014-03-17 | 2015-03-16 | 1,3-benzodioxole derivatives as ezh1 and/or ezh2 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS60022B1 true RS60022B1 (sr) | 2020-04-30 |
Family
ID=54144584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20200240A RS60022B1 (sr) | 2014-03-17 | 2015-03-16 | 1,3-benzodioksol derivati kao ezh1 i/ili ezh2 inhibitori |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US10017500B2 (sr) |
| EP (1) | EP3121175B1 (sr) |
| JP (1) | JP5806438B1 (sr) |
| KR (1) | KR102302830B1 (sr) |
| CN (1) | CN106132954B (sr) |
| AU (1) | AU2015232543B2 (sr) |
| BR (1) | BR112016020621B1 (sr) |
| CA (1) | CA2942883C (sr) |
| CY (1) | CY1122821T1 (sr) |
| DK (1) | DK3121175T3 (sr) |
| ES (1) | ES2774900T3 (sr) |
| HR (1) | HRP20200354T1 (sr) |
| HU (1) | HUE049417T2 (sr) |
| IL (1) | IL247836B (sr) |
| LT (1) | LT3121175T (sr) |
| MX (1) | MX370676B (sr) |
| MY (1) | MY192603A (sr) |
| NZ (1) | NZ723312A (sr) |
| PH (1) | PH12016501813B1 (sr) |
| PL (1) | PL3121175T3 (sr) |
| PT (1) | PT3121175T (sr) |
| RS (1) | RS60022B1 (sr) |
| RU (1) | RU2679131C2 (sr) |
| SG (1) | SG11201607006TA (sr) |
| SI (1) | SI3121175T1 (sr) |
| TW (1) | TWI648275B (sr) |
| WO (1) | WO2015141616A1 (sr) |
| ZA (1) | ZA201605622B (sr) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2679131C2 (ru) | 2014-03-17 | 2019-02-06 | Дайити Санкио Компани, Лимитед | Производное 1,3-бензодиоксола |
| WO2017018499A1 (ja) * | 2015-07-30 | 2017-02-02 | 第一三共株式会社 | 成人ｔ細胞白血病リンパ腫の治療及び／又は予防剤 |
| TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ｅｚｈ２抑制劑 |
| CN106588914B (zh) * | 2015-10-16 | 2018-11-02 | 陈剑 | 具有取代吡啶并咪唑类衍生物，其制备及其在医药上的应用 |
| BR112018007876B1 (pt) | 2015-11-19 | 2023-10-17 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Derivado de benzofurano, seus usos e seu processo de preparação, e composição farmacêutica |
| WO2017199227A1 (en) | 2016-05-20 | 2017-11-23 | S & I Ophthalmic, Llc. | Process for preparation of 3,4-dihydroxy-2-methyl benzoic acid alkylester |
| KR101770302B1 (ko) * | 2016-06-28 | 2017-08-22 | 주식회사 녹십자 | 다이페닐메탄 유도체의 제조방법 |
| CN106727556B (zh) * | 2016-11-30 | 2017-10-20 | 鑫喆喆 | 一种治疗脑损伤的药物组合物 |
| TWI762545B (zh) * | 2016-12-23 | 2022-05-01 | 日商第一三共股份有限公司 | 磺醯胺化合物及其用途 |
| JP7125353B2 (ja) * | 2017-01-19 | 2022-08-24 | 第一三共株式会社 | Ｈｔｌｖ－１関連脊髄症を治療することに用いるための医薬組成物 |
| US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
| EP3615020B1 (en) | 2017-04-26 | 2024-04-10 | University of Cincinnati | Methods, agents, and compositions for the treatment of acute myeloid leukemia |
| US11155537B2 (en) | 2017-05-18 | 2021-10-26 | Jiangsu Hengrui Medicine Co., Ltd. | Crystal of benzofuran derivative free base and preparation method |
| AU2018333913B2 (en) | 2017-09-14 | 2022-11-17 | Daiichi Sankyo Company, Limited | Compound having cyclic structure |
| TWI717656B (zh) | 2017-11-10 | 2021-02-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 苯並呋喃衍生物的製備方法 |
| DK4043466T3 (da) | 2018-01-31 | 2024-09-30 | Mirati Therapeutics Inc | PRC2-inhibitorer |
| EP3781561B1 (en) * | 2018-04-18 | 2024-03-13 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US11919912B2 (en) | 2018-05-21 | 2024-03-05 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2020020374A1 (zh) * | 2018-07-27 | 2020-01-30 | 苏州信诺维医药科技有限公司 | 多取代苯环化合物、制备方法及其用途 |
| TWI837231B (zh) * | 2018-11-29 | 2024-04-01 | 日商第一三共股份有限公司 | 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途 |
| KR102689665B1 (ko) * | 2019-02-19 | 2024-07-31 | 한미약품 주식회사 | 신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도 |
| CN114450279B (zh) * | 2019-07-24 | 2024-07-09 | 星座制药公司 | 结晶形式 |
| US20220257577A1 (en) * | 2019-07-24 | 2022-08-18 | Constellation Pharmaceuticals, Inc. | Ezh2 inhibition in combination therapies for the treatment of cancers |
| KR20220044679A (ko) | 2019-08-08 | 2022-04-11 | 다이이찌 산쿄 가부시키가이샤 | 항ccr4 항체 저항성의 암 치료제 |
| JP2022545467A (ja) | 2019-08-22 | 2022-10-27 | ジュノー セラピューティクス インコーポレイテッド | Ｔ細胞療法とｚｅｓｔｅホモログ２エンハンサー（ＥＺＨ２）阻害剤との併用療法および関連方法 |
| CN115175905A (zh) * | 2020-03-13 | 2022-10-11 | 四川海思科制药有限公司 | Zeste增强子同源物2抑制剂及其用途 |
| JPWO2022009911A1 (sr) | 2020-07-08 | 2022-01-13 | ||
| KR102386403B1 (ko) * | 2020-08-13 | 2022-04-15 | 한미약품 주식회사 | 신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도 |
| US11535629B2 (en) | 2020-08-13 | 2022-12-27 | Hanmi Pharmaceutical Co., Ltd. | Dioxoloisoquinolinone derivatives and use thereof |
| CA3237792A1 (en) | 2021-11-10 | 2023-05-19 | Naho Watanabe | Pharmaceutical composition having excellent dissolution properties |
| CN114149297A (zh) * | 2021-12-07 | 2022-03-08 | 北京中医药大学 | 一种微波辅助的选择性芳基甲醛的绿色合成方法 |
| CN116496263A (zh) * | 2022-01-27 | 2023-07-28 | 江苏天士力帝益药业有限公司 | Ezh1/2抑制剂及其制备和抗肿瘤治疗中的应用 |
| AU2023262308A1 (en) | 2022-04-27 | 2024-10-03 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate with ezh1 and/or ezh2 inhibitor |
| WO2023217018A1 (zh) * | 2022-05-07 | 2023-11-16 | 贝达药业股份有限公司 | Ezh2抑制剂及其在医药上的应用 |
| TW202415655A (zh) | 2022-06-13 | 2024-04-16 | 美商樹線生物科學公司 | １，８—萘啶—２—酮異雙功能ｂｃｌ６降解劑 |
| WO2023244918A1 (en) | 2022-06-13 | 2023-12-21 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| CN115974856B (zh) * | 2022-12-28 | 2023-08-11 | 北京康立生医药技术开发有限公司 | 一种治疗成人t细胞白血病淋巴瘤药物伐美妥司他的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0302486D0 (sv) * | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| US20090012031A1 (en) | 2007-07-03 | 2009-01-08 | The Regents Of The University Of Michigan | EZH2 Cancer Markers |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| EP2773754B1 (en) * | 2011-11-04 | 2016-08-03 | Glaxosmithkline Intellectual Property (No. 2) Limited | Compounds for use in the treatment of T-cell mediated diseases |
| EP2780013A4 (en) * | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| WO2013173441A2 (en) | 2012-05-16 | 2013-11-21 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| WO2014055634A1 (en) | 2012-10-02 | 2014-04-10 | Yale University | Identification of small molecule inhibitors of jumonji at-rich interactive domain 1a (jarid1a) and 1b (jarid1b) histone demethylase |
| US9889180B2 (en) | 2012-11-19 | 2018-02-13 | Agency For Science, Technology And Research | Method of treating cancer |
| RU2679131C2 (ru) | 2014-03-17 | 2019-02-06 | Дайити Санкио Компани, Лимитед | Производное 1,3-бензодиоксола |
-
2015
- 2015-03-16 RU RU2016140420A patent/RU2679131C2/ru active
- 2015-03-16 CN CN201580014878.3A patent/CN106132954B/zh active Active
- 2015-03-16 SG SG11201607006TA patent/SG11201607006TA/en unknown
- 2015-03-16 KR KR1020167024813A patent/KR102302830B1/ko active IP Right Grant
- 2015-03-16 LT LTEP15765525.9T patent/LT3121175T/lt unknown
- 2015-03-16 MY MYPI2016001687A patent/MY192603A/en unknown
- 2015-03-16 TW TW104108302A patent/TWI648275B/zh active
- 2015-03-16 BR BR112016020621-5A patent/BR112016020621B1/pt active IP Right Grant
- 2015-03-16 RS RS20200240A patent/RS60022B1/sr unknown
- 2015-03-16 PL PL15765525T patent/PL3121175T3/pl unknown
- 2015-03-16 US US15/123,523 patent/US10017500B2/en active Active
- 2015-03-16 DK DK15765525.9T patent/DK3121175T3/da active
- 2015-03-16 CA CA2942883A patent/CA2942883C/en active Active
- 2015-03-16 JP JP2015534847A patent/JP5806438B1/ja active Active
- 2015-03-16 EP EP15765525.9A patent/EP3121175B1/en active Active
- 2015-03-16 PT PT157655259T patent/PT3121175T/pt unknown
- 2015-03-16 WO PCT/JP2015/057652 patent/WO2015141616A1/ja active Application Filing
- 2015-03-16 HU HUE15765525A patent/HUE049417T2/hu unknown
- 2015-03-16 SI SI201531090T patent/SI3121175T1/sl unknown
- 2015-03-16 AU AU2015232543A patent/AU2015232543B2/en active Active
- 2015-03-16 NZ NZ72331215A patent/NZ723312A/en unknown
- 2015-03-16 ES ES15765525T patent/ES2774900T3/es active Active
- 2015-03-16 MX MX2016011825A patent/MX370676B/es active IP Right Grant
-
2016
- 2016-08-15 ZA ZA2016/05622A patent/ZA201605622B/en unknown
- 2016-09-15 IL IL247836A patent/IL247836B/en active IP Right Grant
- 2016-09-16 PH PH12016501813A patent/PH12016501813B1/en unknown
-
2018
- 2018-06-07 US US16/002,297 patent/US10954219B2/en active Active
-
2020
- 2020-03-03 HR HRP20200354TT patent/HRP20200354T1/hr unknown
- 2020-03-04 CY CY20201100194T patent/CY1122821T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3121175T (lt) | 1,3-benzodioksazolo dariniai, kaip ezh1 ir (arba) ezh2 inhibitoriai | |
| ZA201704382B (en) | 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of parg | |
| AU2015342774B2 (en) | EZH2 inhibitors and uses thereof | |
| ZA201608077B (en) | Combination, composition, and method of administering the combination or composition to animals | |
| HK1246273B (zh) | 作為溴域抑制劑的取代吡啶 | |
| HK1251566A1 (zh) | 作為hdac1/2抑制劑的呱啶衍生物 | |
| IL247822A0 (en) | History of Tubolisin | |
| EP3201187A4 (en) | Compositions and methods for inhibiting bmp | |
| EP3122355A4 (en) | Compositions and methods for inhibiting bmp | |
| ZA201704116B (en) | 2,3,4,5-tetrahydropyridin-6-amine and 3,4-dihydro-2h-pyrrol-5-amine compound inhibitors of beta-secretase | |
| HRP20182064T1 (hr) | Derivati tetrahidrokinolina kao inhibitori bromodomene | |
| ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| PL3142837T3 (pl) | Sposób modyfikacji drewna | |
| HK1250028A1 (zh) | 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途 | |
| PL3166945T3 (pl) | Nowe pochodne triazolopirymidynonu lub triazolopirydynonu i ich zastosowanie | |
| HK1252767A1 (zh) | 作為eaat3抑制劑的吡唑-吡啶衍生物 | |
| SG11201607745WA (en) | Compositions and methods for producing chemicals and derivatives thereof | |
| PL3113774T3 (pl) | Kompozycje grapiprantu i sposoby ich zastosowania |